US industry buoyed by Congress moves
This article was originally published in Clinica
Executive Summary
US medical device makers are riding a fairly high wave in Congress at present, with Congress poised to finalise in a matter of weeks a bill that would solidify a five-year agreement allowing the Food and Drug Administration to collect user fees from the device industry in exchange for faster and more predictable product reviews. In addition, federal legislators are considering a substantial increase in the FDA's budget, including increases for review of medical devices.
You may also be interested in...
Entries Begin To Roll In For 2024 Industry Awards
Entries have now begun rolling in for the Global Generics & Biosimilars Awards, which returns to Milan this October, Free to enter and attend, the ceremony recognizes the top achievements across the generics, biosimilars and value added medicines industries.
‘I Would Love To Have All The Biologic Assets’ – Formycon’s Glombitza Sets Out Portfolio Approach
In the second part of an exclusive interview, Formycon CEO Stefan Glombitza talks to Generics Bulletin about key regulatory developments in Europe and the US, the firm’s portfolio selection strategy, and upcoming milestones on the horizon.
First Off The Blocks, Fresenius Launches US Tocilizumab Biosimilar
Fresenius Kabi has kicked off competition to Genentech’s Actemra in the US, launching its Tyenne biosimilar version of tocilizumab.